FR940617-1-00053 FR940617-1-00012 (10) Bradbury, S.J., and E.J. Hayden, ``Dettol R Wound Healing,'' unpublished study, Project No. RC 1081, 1978, Comment No. SUP12, Docket No. 75N&hyph;0183, Dockets Management Branch. (11) Maibach, H.I., ``The Effects of Vaseline R Petroleum Jelly and Vaseline R First Aid Carbolated Petroleum Jelly on Epidermal Wound Healing_A Controlled Clinical Laboratory Study,'' unpublished study, Comment No. SUP10, Docket No. 75N&hyph;0183, Dockets Management Branch. (12) Maibach, H.I., ``The Effect of Vaseline R Petroleum Jelly and Vaseline R First Aid Carbolated Petroleum Jelly on Healing of Experimental Skin Wounds,'' unpublished study, Comment No. SUP10, Docket No. 75N&hyph;0183, Dockets Management Branch. (13) Munton, T.J., and J. Prince, ``The Bacteriostatic and Bactericidal Activity of Dettol R Against a Range of Recently Isolated Mesophilic Strains Including Members of the Normal Flora and Cutaneous Pathogens of the Skin,'' unpublished study, No. BL 75/4, 1975, Comment No. SUP3, Docket No. 75N&hyph;0183, Dockets Management Branch. (14) Prince, J., and K.A. Barker, ``A Comparison of the In-Vitro Activity of Dettol R , Hexylresorcinol, and Benzalkonium Chloride,'' unpublished study, No. BL 76/28, 1976, Comment No. SUP3, Docket No. 75N&hyph;0183, Dockets Management Branch. (15) Munton, T.J., and J. Prince, ``The Bactericidal Activity of Dettol R on Skin Artificially Contaminated with Micro-organisms Using the Replica Plating Technique,'' unpublished study, No. BL 75/14, RC 7565, 1975, Comment No. SUP3, Docket No. 75N&hyph;0183, Dockets Management Branch. (16) ``Scientific Information on the `In-vitro' and `In-vivo' Antimicrobial Activity of Dettol R as Determined in the Bacteriological Laboratories of Reckitt and Colman, Hull,'' unpublished report, Comment No. C62, Docket No. 75N&hyph;0183, Dockets Management Branch. (17) Comment No. LET65, Docket No. 75N&hyph;0183, Dockets Management Branch. (18) Comment No. SUP47, Docket No. 75N&hyph;0183, Dockets Management Branch. (19) Guess, W.L., and M.K. Bruch, ``A Review of Available Toxicity Data on the Topical Antimicrobial Chloroxylenol,'' Journal of Toxicology Cutaneous and Ocular Toxicology, 5:233&hyph;262, 1986. (20) Lumley, C.E., and S.R. Walker, ``The Value of Chronic Animal Toxicology Studies of Pharmaceutical Compounds: A Retrospective Analysis,'' Fundamental and Applied Toxicology, 5:1007&hyph;1024, 1985. (21) Comment No. RPT6, Docket No. 75N&hyph;0183, Dockets Management Branch. (22) Davies, J. et al., ``Disinfection of the Skin of the Abdomen,'' British Journal of Surgery, 65:855&hyph;858, 1978. (23) Frazer, J., ``The Effect of Two Alcohol Based Antiseptics on Artificially Contaminated Skin,'' Microbios Letters, 3: (10) 119&hyph;122, 1976. (24) Byatt, M.E., and A. Henderson, ``Preoperative Sterilization of the Perineum: A Comparison of Six Antiseptics,'' Journal of Clinical Pathology, 26:921&hyph;924, 1973. (25) Lowbury, E.J.L., H.A. Lilly, and J. P. Bull, ``Disinfection of Hands: Removal of Transient Organisms,'' British Medical Journal, 2:230&hyph;233, 1964. (26) Caplin, H., and D.C. Chapman, ``A Comparison of Three Commercially Available Antiseptics Against Opportunist Gram-Negative Pathogens,'' Microbios, 16:133&hyph;138, 1976. (27) Comment No. SUP48, Docket No. 75N&hyph;0183, Dockets Management Branch. (28) Comment No. RPT3, Docket No. 75N&hyph;0183, Dockets Management Branch. (29) Comment No. RC6, Docket No. 75N&hyph;0183, Dockets Management Branch. (30) Comment No. C171, Docket No. 75N&hyph;0183, Dockets Management Branch. (31) Letter from W.E. Gilbertson, FDA, to C. Rose, Pennwalt Corp., coded LET54, Docket No. 75N&hyph;0183, Dockets Management Branch. (32) Letter from C. Rose, Pennwalt Corporation, to W.E. Gilbertson, FDA, coded LET59, Docket No. 75N&hyph;0183, Dockets Management Branch. (33) Letters from W.E. Gilbertson, FDA, to J. Nalls, Ferro Corp., C. Rose, Pennwalt Corp., M.E. Garabedian, Dexide, Inc., M. Berdick, Chesebrough-Ponds, Inc., W.F. Stephen, Scientific and Regulatory Services, H.S. Chapman, Chemical Specialties, Inc., C.A. Wiseman, Sani-Fresh, Division of Envair, Inc., J. Rowan, Seagull Chemical, Inc., coded LET70, LET71, LET72, LET73, LET74, LET75, LET76, and LET77, respectively, in Docket No. 75N&hyph;0183, Dockets Management Branch. (34) Comment No. LET65, volumes 1 through 3, Docket No. 75N&hyph;0183, Dockets Management Branch. (35) Memorandum of meeting between representatives of Dexide, Inc., Ferro Corp., and FDA, coded MM8, Docket No. 75N&hyph;0183, Dockets Management Branch. (36) Stavchansky, ``Computer Simulations of Chloroxylenol,'' unpublished report, Comment No. SUP47, Docket No. 75N&hyph;0183, Dockets Management Branch. (37) Cabana, B.E., and E.D. Purich,''Comparative Metabolism and Pharmacokinetics of Chloroxylenol (PCMX) in Animals and Man,'' unpublished report, Comment No. RPT6, Volume 7, Docket No. 75N&hyph;0183, Dockets Management Branch.
